Brendan D. Price, Ph.D., Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA First–Year Funding Summary, going into the second-year Pediatric high-grade gliomas (pHGG) have few treatment options and most children diagnosed only survive for 1-2 years. Identifying new treatments is therefore of the highest priority. Work in the lab is focused …
Stephen C. Mack, Ph.D., Baylor College of Medicine, Texas Children’s one-year study, final summary We are grateful for support provided by the CBTF and funders that have allowed us to pursue our project on the characterizing “The Role of MOS Proto-Oncogene in H3.3K27M Diffuse Intrinsic Pontine Glioma”. Diffuse intrinsic pontine glioma (DIPG) remains a fatal …
Marius Wernig, M.D., Ph.D. Stanford University School of Medicine The lysine 27 to methionine substitution in histone variant H3.3 (H3.3-K27M) is the most common mutation in pediatric high grade gliomas. Recent studies have demonstrated that this mutation leads to a global reduction of H3K27 trimethylation in a dominant manner by sequestering an enzymatic subunit of …